MINT-ACYCLOVIR TABLET
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
21-01-2022
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
ACYCLOVIR
Fáanlegur frá:
MINT PHARMACEUTICALS INC
ATC númer:
J05AB01
INN (Alþjóðlegt nafn):
ACYCLOVIR
Skammtar:
200MG
Lyfjaform:
TABLET
Samsetning:
ACYCLOVIR 200MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
15G/50G
Gerð lyfseðils:
Prescription
Vörulýsing:
Active ingredient group (AIG) number: 0115506002; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2022-01-25
Vara einkenni
PRODUCT MONOGRAPH
PR
MINT-ACYCLOVIR
ACYCLOVIR TABLETS USP
200 MG, 400 MG AND 800 MG
ANTIVIRAL AGENT
MINT PHARMACEUTICALS INC.
DATE OF PREPARATION:
6575 DAVAND DRIVE
JANUARY 21, 2022
MISSISSAUGA, ONTARIO
L5T 2M3
Control No. 239932
_MINT-ACYCLOVIR Product Monograph_
_ _
_Page 2 of 37 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3 SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
6
DRUG INTERACTIONS
..................................................................................................
9
DOSAGE AND ADMINISTRATION
...............................................................................
9
OVERDOSAGE
..............................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
.............................................................12
STORAGE AND STABILITY
.........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................14
PART II: SCIENTIFIC
INFORMATION.......................................................................
15
PHARMACEUTICAL INFORMATION
..........................................................................15
CLINICAL TRIALS
........................................................................................................15
DETAILED PHARMACOLOGY
....................................................................................16
VIR
Lestu allt skjalið
